API manufacturers in India are making efforts to strengthen their marketing capacity by
improving production yields, modifying production processes, and increasing sales. More
than 30% of the APIs manufactured in India are exported to countries such as the US, the
UK, Japan, etc. The total production market of API in India was valued at approximately
US$ 11 Billion forecasted to grow at a CAGR of around 9% during the period of FY 2019 FY
2022.
Of the total domestic consumption, approximately 32% was imported. Of the total
imports, China alone accounts for 57-60% of the APIs imported by India. The remaining
imports are from countries such as Italy, Germany, Malaysia, and others. These facts
indicate that there is plentiful scope for the domestic API market to grow, if the
manufacturers are able to produce the required amount of APIs on their own, rather than
importing it from other countries.
The Share of India in the Global API market has increased as the Indian API industry
has been supplying good quality API to top pharmaceutical companies, both domestically and
globally. Moreover, the Indian API industry has gained recognition worldwide due to its
high quality of APIs.
According to RNCOS analysis, the Indian API domestic consumption market will grow at a
CAGR of around 10% from FY 2019 to FY 2022. The Indian Government made the announcement of
2019 being the ‘Year of APIs.
Apart from this, players are manufacturing complex APIs by using latest technologies.
This serves as a key differentiating factor of research of each company. Players are also
expanding their global footprint, announcing new distribution channels and opening new
manufacturing facilities.
Drivers & Challenges
A major chunk of the population lives on less than US$ 1 per day, and most of them have
to pay out of their own pockets for medical services. Out-of-pocket spending in India is
over four times higher than public spending on healthcare. Therefore, there is a rising
need for advanced drugs that will help people to recover quickly at lower cost.
Personal disposable income in India has grown at a CAGR of approximately 12%. With rise
in income, consumption patterns have changed and a new middle class has emerged, which is
growing at a fast pace. The rising middle class population will be a predominant factor
for more value based healthcare facilities. Meanwhile, India has limited healthcare
insurance coverage (both private and government) compared to other countries, which
results in nearly 80% of the total out-of-the-pocket expenditure on medical facilities.
Consequently, there are significant opportunities for businesses to flourish in primary
healthcare as well as wellness and disease management.
India is witnessing a rise in ageing population. According to UN estimates, the
percentage of old people (60 years or above) in India will rise from 8.9% in 2019 to 12.5%
in 2030. Furthermore, by 2050, 19.4% of the total Indias population will age above 60
years. The country will also witness rise in the old age dependency ratio from 13% in 2000
to 32.8% in 2050. Precisely, three Indians in the working age population will have to take
care of one elderly by 2050. The growing burden of an ageing population will increase the
consumption of pharmaceutical products, which in turn will generate a greater demand for
APIs.
India is a developing nation where a major portion of the population lives below the
poverty line. According to World Bank, the poverty rate in India is 12.4%. These people
and many others require medication which is economical. Consequently, there has been a
rise in the demand for generic medicines, which are made with the help of APIs. A further
increase in demand for generic medicines will propel growth of the Indian API market.
Recently government has made it mandatory to give prescription of generic names of drugs.
Market Segmentation
On the basis of the type of manufacturing process that an API producing company opts
for, the API market is segmented into captive and merchant markets. The captive market
includes the APIs produced by pharmaceutical companies themselves for their own needs,
while the merchant market for APIs includes those APIs that are sold by third parties. In
FY 2016, the captive market of APIs held a share of more than 65% in the Indian API
market. On the other hand, the merchant market held a share of over 30%. Looking at the
initiatives taken by the government to promote domestic manufacturing of APIs, the captive
market is bound to grow in the coming years.
The domestic Indian API market is further segmented on the basis of the type of API.
Chemical or small molecule APIs lead the market compared to the Biotech APIs. In FY 2019,
Chemical APIs accounted for 70% of the Indian API market.
Out of these therapeutic areas, a major share of 32% was occupied by the
anti-infectives.
Government Initiatives
The Government of India is adopting various measures to promote its ‘Make in
India campaign in the pharmaceutical sector, so that there is 100% production of APIs
domestically. For this purpose a committee has been established. This committee has
recommended the development of Mega Parks for APIs with common facilities like:
Effluent Treatments Plants (ETPs) Testing Facilities
Captive Power Plants/Assured Power Supply by State Systems
Common Utilities/Services such as storage, testing laboratories, IPR management,
designing, etc.
The Department of Pharmaceutical has planned to launch a venture capital fund of INR
1,000 Crore. This fund will provide support to the start-ups in the pharmaceutical
industry. The venture capital fund will be used by the companies to carry out research and
development of novel active pharmaceutical ingredients and formulations. This move would
give a boost to the domestic pharmaceutical industry, and provide cheaper loans to
entities looking to establish or upgrade manufacturing facilities.
Opportunities and Recommendations
Presently, Indian API industry has a major presence in the generic drug APIs market. If
the government increases the budget for R&D, the pharma experts will be able to work
better with increased resources towards the development of novel APIs such as ionic
liquids.
Presently, the generic drugs market is dominated by branded generic drugs. This is
causing a hindrance to the sales of unbranded generic drugs by small or medium scale
manufacturers in India. This in turn affects the generic drug API market. However, the
revival of Jan Aushadhi Scheme and Free Essential Drug scheme by the state & central
governments would prove to be an opportunity for the domestic generic API manufactures to
conquer the generic drug API market.
The rising geriatric population in the country and increased awareness among people
about healthcare is causing an increase in the demand for new medical products. Areas such
as oncology, diabetes, respiratory disorders, cardiovascular diseases, etc. can be the
potential focus segments. Research experts should focus on the development of novel APIs
for these emerging therapeutic segments, which offer opportunities for growth to this
industry.
| For Nutraplus India Limited |
| Mukesh D. Naik |
Nitin M. Desai |
| Managing Director |
Director |
| DIN: 00412896 |
DIN: 08278643 |
Place: Mumbai Date: November 16, 2020
ANNEXURE II
DETAILS OF REMUNERATION
Details pertaining to remuneration as required under Section 197(12) of the Companies
Act, 2013 read with Rule 5(1) of the Companies (Appointment and Remuneration of Managerial
Personnel) Rules, 2014
i. The ratio of the remuneration of each Director to the median remuneration of the
employees of the Company for the financial year 2019-20 and the percentage increase in
remuneration of each Director during the Financial Year 2019-20 are as under:
| Sr. No. Name of Directors |
Remuneration (‘in lakh) |
% increase/decrease in Remuneration in the FY 2019-20 |
Ratio of Remuneration of each director/to Median Remuneration to
employee |
| 1. Mr. Mukesh Naik, Managing Director |
30.00 |
NIL |
5.45 |
| 2. Mr. Dilip Pimple, Whole-time Director |
15.40 |
NIL |
2.80 |
| 3. Mr. Uday Desai Chief Executive Officer |
18.00 |
18.00 |
3.27 |
| 4. Mr. Chirag Mehta* Chief Financial Officer |
1.14 |
1.10 |
0.21 |
| 5. Ms. Nancy Napoleon Company Secretary |
3.90 |
3.84 |
0.71 |
*Mr. Chirag Mehta was appointed on the post of the Chief Financial Officer w.e.f. March
30, 2019 and resigned w.e.f. 27.05.2020
i. The percentage increase in the median remuneration of employees in the Financial
Year: ii. The Median remuneration of the employees in the financial year 2019-20 was Rs.
5.50 Lakhs as compared to the financial year 2018-19 was Rs. 2.60 Lakhs. iii. There were 9
permanent employees on the rolls of the Company as on 31st March, 2020: iv.
Average percentile decrease in the median remuneration of comparable employees in the
Financial Year 2019-20 other than the managerial personnel was 12.44% and there is no
change in salary of the Managerial personnel. v. Affirmation that the remuneration is as
per the Nomination and Remuneration Policy of the Company: It is hereby affirmed that the
remuneration paid is as per the Policy for Nomination & Remuneration of the Director,
Key Managerial Personnel and other Employees. vi. The statement containing names of top
ten employees in terms of remuneration drawn and the particulars of employees as required
under Section 197 (12) of the Act read with Rules 5(2) of the Companies (Appointment and
Remuneration of Managerial Personnel) Rules, 2014 is provided in a separate Annexure
forming part of this Report and the accounts are being sent to the Members excluding the
aforesaid Annexure. In terms of Section 136 of the Act, the said Annexure is open for
inspection at the Registered Office of the Company. Any shareholder interested in
obtaining a copy of the same may write to the Company Secretary.
For and on behalf of the Board of Directors of Nutraplus India Limited
| Dilip Pimple |
Mukesh Naik |
| Whole-time Director |
Chairman & Managing Director |
| DIN:02433809 |
DIN: 00412896 |
Place: Mumbai Date: November 16, 2020
Details pertaining to remuneration as required under Section 197(12) read with Rule 5
(2) of Companies (Appointment and Remuneration of Managerial Personnel) Rules, 2014 a) Top
ten employees of the Company terms of remuneration drawn during the year:
| SR. NO. |
1 |
2 |
3 |
4 |
5 |
6 |
7 |
8 |
9 |
| NAME |
MUKESH NAIK |
UDAY DESAI |
VIMAL AGARWAL |
ABHIJIT JADHAV |
ALPA SHAH |
BHAGVATILAL MEHTA |
LOUIS RUMAO |
NANCY NAPOLEON |
UJWALA CHAVAN |
| DESIGNATION |
CHAIRMAN & MANAGING |
SALES MANAGER |
ACCOUNT MANAGER |
PURCHASE MANAGER |
ACCOUTANT |
SALES MANAGER |
LEAGAL & ADMIN |
COMPANY SECERTARY |
ACCOUNT OFFICER |
| REMUNERATI ON PAID |
30,00,000.00 |
18,00,000.00 |
7,49,996.00 |
6,99,995.00 |
5,50,000.00 |
5,03,000.00 |
4,63,400.00 |
3,90,000.00 |
2,60,000.00 |
| NATURE OF EMPLOYMENT |
FULL TIME |
FULL TIME |
FULL TIME |
FULL TIME |
FULL TIME |
FULL TIME |
FULL TIME |
FULL TIME |
FULL TIME |
| QUALIFICATIO NS |
B.E. (Chemical Eng) |
B.E. (Chemical Eng) |
B.COM |
M.M.S. |
B.COM |
B.COM |
B.COM |
C.S. |
B.COM |
| EXPERIENCE (YEARS) |
30 |
20 |
23 |
25 |
25 |
6 |
22 |
7 |
11 |
| DATE OF COMMERNCE OF EMPLOYMENT |
20.03.1995 |
15-03-2002 |
20.03.2018 |
05.07.2013 |
20.09.1995 |
16.01.2012 |
16.12.1996 |
15.03.2019 |
20.09.2007 |
| AGE (YEARS) |
65 |
37 |
50 |
44 |
42 |
33 |
50 |
32 |
38 |
| PREVIOUS EMPLOYMENT |
N.A. |
N.A. |
N.A. |
N.A. |
N.A. |
N.A. |
N.A. |
N.A. |
N.A. |
| PERCENTAGE OF EQUITY |
NIL |
NIL |
NIL |
NIL |
NIL |
NIL |
NIL |
NIL |
NIL |
| WHETHER RELATIVE OF |
NO |
NO |
NO |
NO |
NO |
NO |
NO |
NO |
NO |
ANNEXURE IV
EXTRACT OF ANNUAL RETURN
As on financial year ended on 31st March 2020
[Pursuant to section 92(3) of the Companies Act, 2013 and rule 12(1) of the
Companies (Management and Administration)
Rules, 2014]
I. REGISTRATION AND OTHER DETAILS:
| CIN |
L24230MH1990PLC055347 |
| Registration Date |
06/02/1990 |
| Name of the Company |
Nutraplus India Ltd. |
| Category / Sub-Category of the Company |
Company limited by Shares Non-govt company |
| Address of the Registered office and contact details |
Plot No. N-92, MIDC- Tarapur, Boisar, Thane- 401 506. |
| Whether Listed company |
Yes |
| Name, Address and Contact details of Registrar and Transfer Agent, if any: |
Link Intime India Pvt. Ltd. (Sharex Dynamic (India) Pvt. Ltd. merged
with Link Intime India Pvt. Ltd.) C101, 247 Park, LBS Marg, Vikhroli (West), Mumbai 400
083. support@sharexindia.com |
II. PRINCIPAL BUSINESS ACTIVITIES OF THE COMPANY
All the business activities contributing 10% or more of the total turnover of the
company shall be stated:-
| Sl. No. Name and Description of main products/ services |
NIC Code of the Product/ service |
% to total turnover of the company |
| 1 Drugs and Pharmaceuticals |
21001 |
100 |
III. PARTICULARS OF HOLDING, SUBSIDIARY AND ASSOCIATE COMPANIES
| Sr. No. Name and address of the Company |
CIN / GLN |
Holding/ subsidiary/associate |
% of shares held |
Applicable section |
| NIL |
|
|
|
|
IV. SHARE HOLDING PATTERN (Equity Share Capital Breakup as percentage of Total
Equity): i. Category-wise Share Holding:
| Category & Name of the Shareholders |
No. of Shares held at the beginning of the year |
No. of Shares held at the end of the year |
% Change during the year |
|
Demat |
Physica l |
Total |
% of Total Shares |
Demat |
Physical |
Total |
% of Total Shares |
|
| A. Promoters |
|
|
|
|
|
|
|
|
|
| (1) Indian |
|
|
|
|
|
|
|
|
|
| a)Individual/HUF |
13658920 |
0 |
13658920 |
40.066 |
13658920 |
0 |
13658920 |
40.066 |
0 |
| b) Central Govt |
|
0 |
|
|
|
0 |
|
|
0 |
| c) State Govt(s) |
|
0 |
|
|
|
0 |
|
|
0 |
| d) Bodies Corp. |
|
0 |
|
|
|
0 |
|
|
0 |
| e) Banks / FI |
|
0 |
|
|
|
0 |
|
|
0 |
| f) Any other |
|
0 |
|
|
|
0 |
|
|
0 |
| Sub-total(A)(1): |
13658920 |
0 |
13658920 |
40.066 |
13658920 |
0 |
13658920 |
40.066 |
0 |
| (2) Foreign |
|
|
|
|
|
|
|
|
|
| a) NRIs - Individuals |
|
0 |
|
|
|
0 |
|
|
0 |
| b) Other - Individuals |
|
0 |
|
|
|
0 |
|
|
0 |
| c) Bodies Corp. |
|
0 |
|
|
|
0 |
|
|
0 |
| d) Banks / FI |
|
0 |
|
|
|
0 |
|
|
0 |
| e) Any other |
|
0 |
|
|
|
0 |
|
|
0 |
| Sub-total (A)(2): |
|
0 |
|
|
|
0 |
|
|
0 |
| Total shareholding of Promoter (A) = (A)(1)+(A)(2) |
13658920 |
0 |
13658920 |
40.066 |
13658920 |
0 |
13658920 |
40.066 |
13658920 |
| B. Public Shareholding |
|
|
|
|
|
|
|
|
|
| (1) Institutions |
|
|
|
|
|
|
|
|
|
| a) Mutual Funds |
0 |
8360 |
8360 |
0.025 |
0 |
8360 |
8360 |
0.025 |
0.000 |
| b) Banks/FI |
1540 |
220 |
1760 |
0.005 |
0 |
220 |
220 |
0.001 |
-0.0004 |
| c)Central Government |
|
0 |
|
|
|
|
|
|
|
| d) State Govt(s) |
|
0 |
|
|
|
|
|
|
|
| d)Venture Capital Funds |
|
0 |
|
|
|
|
|
|
|
| e)Foreign Portfolio Investors |
|
0 |
|
|
|
|
|
|
|
| f)Insurance Companies |
|
0 |
|
|
|
|
|
|
|
| g) FIIs |
|
0 |
|
|
|
|
|
|
|
| h)Foreign Venture Capital Funds |
|
0 |
|
|
|
|
|
|
|
| i) Others (specify) |
0 |
0 |
0 |
0 |
0 |
|
|
|
|
| Sub-total (B)(1): |
1540 |
8580 |
10120 |
0.03 |
0 |
8580 |
8580 |
0.026 |
-0.004 |
| (2)Non-Institutions |
|
|
|
|
|
|
|
|
|
| a) Bodies Corp. |
|
|
|
|
|
|
|
|
|
| (i) Indian |
1963961 |
18260 |
1982221 |
5.814 |
1638202 |
18260 |
1656462 |
4.859 |
-0.955 |
| ii) Overseas |
|
0 |
|
|
|
0 |
|
|
0.000 |
| b) Individuals |
|
|
|
|
|
|
|
|
|
| i) Individual shareholders holding nominal share capital upto Rs. 2 lacs |
4639983 |
1031050 |
5671033 |
16.635 |
4737331 |
1011695 |
5749026 |
16.864 |
0.229 |
| ii) Individual shareholders holding nominal share capital in excess of Rs 2 lacs |
11652139 |
21560 |
11673699 |
34.243 |
12023561 |
21560 |
12045121 |
35.322 |
1.089 |
| c) Others (specify) |
|
|
|
|
|
|
|
|
|
| Non Resident |
517834 |
263120 |
780954 |
2.291 |
679632 |
263120 |
942752 |
2.765 |
0.474 |
| Overseas Corporate Bodies |
|
0 |
|
|
|
|
|
|
|
| Foreign Nationals |
|
0 |
|
|
|
|
|
|
|
| Clearing Members |
314139 |
0 |
314139 |
0.921 |
30225 |
0 |
30225 |
0.089 |
-0.832 |
| Trusts |
|
0 |
|
|
|
|
|
|
|
| Foreign Bodies - D R |
|
0 |
|
|
|
|
|
|
|
| Sub-total(B)(2): |
19088056 |
1333990 |
20422046 |
59.904 |
19108951 |
1314635 |
20423586 |
59.909 |
0.005 |
| Total Public Shareholding (B)=(B)(1)+(B)(2) |
19089596 |
1342570 |
20432166 |
59.934 |
19108951 |
1323215 |
20432166 |
59.935 |
0.001 |
| C. Shares held by Custodian for GDRs & ADRs |
|
0 |
|
|
|
|
|
|
0.000 |
| Grand Total (A+B+C) |
32748516 |
1342570 |
34091086 |
100.00 |
32767871 |
1323215 |
34091086 |
100.00 |
0.00 |
ii. SHAREHOLDING OF PROMOTERS:
| Sl. No. Shareholders Name |
Shareholding at the beginning of the year |
Share holding at the end of the Year |
|
|
No. of Shares |
% of total Shares of the Company |
% of Shares Pledged/ encumbered to total shares |
No. of Shares |
% of total Shares of the Company |
% of Shares Pledged / encumbered to total shares |
% change in share holding during the year |
| 1. Naik Mukesh Dhirubhai |
3888060 |
11.405 |
0 |
3888060 |
11.405 |
0 |
0.00 |
| 2. Uday Desai |
3745280 |
10.986 |
0 |
3745280 |
10.986 |
0 |
0.00 |
| 3. Nidhi M Naik |
3300000 |
9.68 |
0 |
3300000 |
9.68 |
0 |
0.00 |
| 4. Gita Mukesh Naik |
2725580 |
7.995 |
0 |
2725580 |
7.995 |
0 |
0.00 |
| Total |
13658920 |
40.066 |
0 |
13658920 |
40.066 |
0 |
0.00 |
iii. CHANGE IN PROMOTERS SHAREHOLDING:
| Sl. No. Sharehold ers Name |
Shareholding at the beginning of the year |
Shareholding at the end of the year |
|
|
No.of Shares at the beginning /end of the Year |
% of the Shares of the company |
Date |
Increasing/De creasing in shareholding |
Reason |
No. of shares |
% of total shares of the Company |
| 1. Naik Mukesh Dhirubhai |
3888060 |
11.405 |
01-04-2019 |
NIL |
|
|
|
| -Closing Balance |
|
|
31-03-2020 |
|
|
3888060 |
11.405 |
| 2. Uday Desai |
3745280 |
10.986 |
01-04-2019 |
NIL |
|
|
|
| Closing Balance |
|
|
31-03-2020 |
|
|
3745280 |
10.986 |
| 3. Nidhi M Naik |
3300000 |
9.68 |
01-04-2019 |
NIL |
|
|
|
| -Closing Balance |
|
|
31-03-2020 |
|
|
3300000 |
9.68 |
| 4. Gita Mukesh Naik |
2725580 |
7.995 |
01-04-2019 |
NIL |
|
|
|
| -Closing Balance |
|
|
31-03-2020 |
|
|
2725580 |
7.995 |
V. SHAREHOLDING PATTERN OF TOP TEN SHAREHOLDERS (OTHER THAN DIRECTORS, PROMOTERS
AND HOLDERS OF GDRS AND ADRS):
| Sr. No Name |
No. of Shares at the beginni ng /end of the Year |
% of the Shares of the company |
Date |
Increasing/ Decreasing in shareholdin g |
Reason |
No. of shares |
% of total Shares of the company |
| 1 MANOJ MITTAL |
1483270 |
4.351 |
01-04-2019 |
|
|
|
|
| -CLOSING BALANCE |
|
|
31-03-2020 |
|
No Change |
1483270 |
4.351 |
| 2 RAMESH SINGHAL |
1090476 |
3.199 |
01-04-2019 |
|
|
|
|
|
|
|
26-07-2019 |
-522876 |
Sold |
567600 |
1.655 |
|
|
|
02-08-2019 |
-522876 |
Buy |
1090476 |
3.199 |
| -CLOSING BALANCE |
|
|
31-03-2020 |
|
|
1090476 |
3.199 |
| 3 SANGEETHA S |
146590 |
0.43 |
01-04-2019 |
|
|
|
|
|
|
|
08-11-2019 |
534490 |
Buy |
681080 |
1.998 |
| Closing Balance |
|
|
31-03-2020 |
|
|
681080 |
1.998 |
| 4 VARUN SINGHAL |
644200 |
1.89 |
01-04-2019 |
|
|
|
|
| -CLOSING BALANCE |
|
|
31-03-2020 |
|
No Change |
644200 |
1.89 |
| 5 KISHOR PUNAMCHAND OSTWAL |
600000 |
1.76 |
01-04-2019 |
|
|
|
|
|
|
|
20-12-2019 |
5000 |
Buy |
605000 |
1.775 |
|
|
|
27-12-2019 |
-3000 |
Sold |
602000 |
1.776 |
|
|
|
03-01-2020 |
-2000 |
Sold |
600000 |
1.76 |
| -Closing Balance |
|
|
31-03-2020 |
|
|
600000 |
1.76 |
| 6 CNI RESEARCH LIMITED |
652730 |
1.915 |
01-04-2019 |
|
|
|
|
|
|
|
07-06-2019 |
-26000 |
Sold |
626730 |
1.838 |
|
|
|
14-06-2019 |
26000 |
Buy |
652730 |
1.915 |
|
|
|
05-07-2019 |
20000 |
Buy |
672730 |
1.973 |
|
|
|
13-09-2019 |
-20000 |
Sold |
652730 |
1.915 |
|
|
|
20-09-2019 |
-24000 |
Sold |
628730 |
1.844 |
|
|
|
27-09-2019 |
21000 |
Buy |
649730 |
1.906 |
|
|
|
04-10-2019 |
23000 |
Buy |
672730 |
1.973 |
|
|
|
18-10-2019 |
-10000 |
Sold |
662730 |
1.944 |
|
|
|
25-10-2019 |
5000 |
Buy |
667730 |
1.959 |
|
|
|
01-11-2019 |
5000 |
Buy |
672730 |
1.973 |
|
|
|
10-01-2020 |
-39268 |
Sold |
633462 |
1.858 |
|
|
|
17-01-2020 |
-30918 |
Sold |
602544 |
1.767 |
|
|
|
24-01-2020 |
-25173 |
Sold |
577371 |
1.694 |
|
|
|
31-01-2020 |
-9361 |
Sold |
568010 |
1.666 |
| Closing Balance |
|
|
31-01-2020 |
|
|
568010 |
1.666 |
| 7 B N MITTAL HUF |
329535 |
0.967 |
01-04-2019 |
|
|
|
|
| -CLOSING BALANCE |
|
|
31-03-2020 |
|
No Change |
329535 |
0.967 |
| 8 PRASHANT KOTHARI |
184000 |
0.54 |
01-04-2019 |
|
|
|
|
|
|
|
05-04-2019 |
9149 |
Buy |
193149 |
0.567 |
|
|
|
29-06-2019 |
5000 |
Buy |
198149 |
0.581 |
|
|
|
12-07-2019 |
15000 |
Buy |
213149 |
0.625 |
|
|
|
13-12-2019 |
-202 |
Sold |
212947 |
0.625 |
|
|
|
21-02-2020 |
30000 |
Buy |
242947 |
0.713 |
| -CLOSING BALANCE |
|
|
31-03-2020 |
|
|
242947 |
0.713 |
| 9 BHARAT K BANKA HUF |
242000 |
0.71 |
01-04-2019 |
|
|
|
|
| -Closing Balance |
|
|
31-03-2020 |
|
No Change |
242000 |
0.71 |
| 10 JYOTIVARDHA N JAIPURIA |
240000 |
0.704 |
01-04-2019 |
|
|
|
|
| -Closing Balance |
|
|
31-03-2020 |
|
No Change |
242000 |
0.704 |
VI. SHAREHOLDING OF DIRECTORS AND KEY MANAGERIAL PERSONNEL:
| Sl. No. Shareholders Name |
Shareholding at the beginning of the year |
Shareholding at the end of the year |
|
|
No.of Shares at the beginning /end of the Year |
% of the Shares of the compan y |
Date |
Increasing/Dec reasing in shareholding |
Reason |
No. of shares |
% of total shares of the Company |
| 1. Naik Mukesh Dhirubhai |
3888060 |
11.405 |
01-04-2019 |
NIL |
|
|
|
| -Closing Balance |
|
|
31-03-2020 |
|
|
3888060 |
11.405 |
| 2. Uday Desai |
3745280 |
10.986 |
01-04-2019 |
NIL |
|
|
|
| Closing Balance |
|
|
31-03-2020 |
|
|
3745280 |
10.986 |
| 3. Nidhi M Naik |
3300000 |
9.68 |
01-04-2019 |
NIL |
|
|
|
| -Closing Balance |
|
|
31-03-2020 |
|
|
3300000 |
9.68 |
| 4. Gita Mukesh Naik |
2725580 |
7.995 |
01-04-2019 |
NIL |
|
|
|
| -Closing Balance |
|
|
31-03-2020 |
|
|
2725580 |
7.995 |
VII. INDEBTEDNESS:
Indebtedness of the Company including interest outstanding/accrued but not due for
payment.
|
Secured Loans excluding deposits |
Unsecured Loans |
Deposits |
Total Indebtedness |
| Indebtedness at the beginning of the |
financial year |
|
|
|
| i) Principal Amount |
74,93,21,922 |
- |
- |
74,93,21,922 |
| ii) Interest due but not paid |
- |
- |
- |
- |
| iii) Interest accrued but not due |
42,08,674 |
- |
- |
42,08,674 |
| Total (i+ii+iii) |
75,35,30,596 |
- |
- |
75,35,30,596 |
| Change in Indebtedness during the financial year |
|
|
|
|
| Addition |
73,21,34,013 |
--- |
--- |
73,21,34,013 |
| Reduction |
72,69,13,574 |
--- |
--- |
72,69,13,574 |
| Net Change |
52,20,439 |
--- |
--- |
52,20,439 |
| Indebtedness at the end of the financi |
al year |
|
|
|
| i) Principal Amount |
75,87,51,035 |
--- |
--- |
75,87,51,035 |
| ii) Interest due but not paid |
--- |
--- |
--- |
— |
| iii) Interest accrued but not due |
--- |
--- |
--- |
--- |
| Total (i+ii+iii) |
75,87,51,035 |
— |
— |
75,87,51,035 |
VIII. REMUNERATION OF DIRECTORS AND KEY MANAGERIAL PERSONNEL: A. Remuneration
to Managing Director, Whole-time Directors and/or Manager:
| Sr. No. Particulars of Remuneration |
Name of MD/ WTD/ Mukesh D. Naik Managing Director |
Manager Dilip K. Pimple Whole-Time Director |
Total Amount |
| 1 Gross salary |
|
|
|
| (a) Salary as per provisions contained in section 17(1) of the Income-tax Act, 1961 |
30,00,000 |
15,40,000/- |
45,40,000 |
| (b) Value of perquisites u/s 17(2) Income-tax Act, 1961 |
- |
- |
- |
| (c) Profits in lieu of salary under section 17(3) Income-tax Act, 1961 |
|
|
|
| 2 Stock Option |
- |
- |
- |
| 3 Sweat Equity |
- |
- |
- |
| 4 Commission |
- |
- |
- |
| - as % of profit |
- |
- |
- |
| - others, specify |
- |
- |
- |
| 5 Others, please specify |
- |
- |
- |
| Total (A) |
30,00,000 |
15,40,000/- |
45,40,000 |
| Ceiling as per the Act |
|
|
|
B. REMUNERATION TO OTHER DIRECTORS:
| Particulars of Remuneration |
Independent Directors |
Total Amount |
| Name of Directors |
Mr. Nitin M. Desai |
Mr. Vinod L. Parab |
Mr. Prameshkum ar B. Mehta |
*Mrs. Leena Parashar Chitalia |
|
| Fee for attending board / committee meetings |
5000.00 |
2500.00 |
Nil |
2500.00 |
10000.00 |
| Commission |
- |
- |
- |
Nil |
- |
| Others, specify please |
- |
- |
- |
Nil |
- |
| Total(1) |
5000.00 |
2500.00 |
Nil |
2500.00 |
10000.00 |
*Mrs. Leena Parashar Chitalia has been appointed as an additional director w.e.f. July
19, 2019 Other Non-Executive Directors
| Name of Director |
Ms. Nidhi Naik** |
| Fee for attending board / committee meetings |
Nil |
| Commission |
|
| Others, please specify |
|
| Total (2) |
|
| Total (B)=(1+2) |
|
| Total Managerial Remuneration |
Nil |
| Overall Ceiling as per the Act |
|
** Ms. Nidhi Naik has resigned from the post of Executive Director w.e.f. 24th
July, 2019. C. REMUNERATION TO KEY MANAGERIAL PERSONNEL OTHER THAN MD/MANAGER/WTD
| Sr. No. Particulars of Remuneration |
Key Managerial Personnel |
|
CEO |
Company Secretary |
CFO * |
Total |
| 1 Gross salary |
18,00,000 |
3,90,000 |
Nil |
21,90,000 |
| (a) Salary as per provisions contained in section 17(1) of the Income-tax Act, 1961 |
|
|
|
|
| (b) Value of perquisites u/s 17(2) Income-tax Act, 1961 |
- |
- |
- |
- |
| (c) Profits in lieu of salary under section 17(3) Income tax Act, 1961 |
|
|
|
|
| 2 Stock Option |
- |
- |
- |
- |
| 3 Sweat Equity |
- |
- |
- |
- |
| 4 Commission |
- |
- |
- |
- |
| - as % of profit |
- |
- |
- |
- |
| - others, specify |
- |
- |
- |
- |
| 5 Others, please Specify |
|
|
|
|
| Total |
18,00,000 |
3,90,000 |
|
21,90,000 |
* Mr. Chirag R. Mehta has resigned from the post of Chief Financial Officer w.e.f. 27th
May, 2019. IX. PENALTIES / PUNISHMENT/ COMPOUNDING OF OFFENCES:
| Type |
Section of the Companies Act |
Brief Description |
Details of Penalty / Punishment/ Compounding fees imposed |
Authority [RD /NCLT/ COURT] |
Appeal made, if any (give Details) |
| A. COMPANY |
|
|
|
|
|
| Penalty |
|
|
|
|
|
| Punishment |
|
|
NIL |
|
|
| Compounding |
|
|
|
|
|
| B. DIRECTORS |
|
|
|
|
|
| Penalty |
|
|
NIL |
|
|
| Punishment |
|
|
|
|
|
| Compounding |
|
|
|
|
|
| C. OTHER OFFICERS |
IN DEFAULT |
|
|
|
|
| Penalty |
|
|
NIL |
|
|
| Punishment |
|
|
|
|
|
| Compounding |
|
|
|
|
|
For and on behalf of the Board of Directors of Nutraplus India Ltd. Sd/-
Mukesh Naik
Chairman & Managing Director DIN: 00412896
Place: Mumbai
Date: November 16, 2020
+91-9892691696
